{"id":3094,"date":"2023-08-09T07:45:10","date_gmt":"2023-08-09T07:45:10","guid":{"rendered":"https:\/\/limcr.rup-dev.net\/tumor-immunology-geisberger-group\/"},"modified":"2024-02-14T07:54:40","modified_gmt":"2024-02-14T07:54:40","slug":"tumor-immunology-geisberger-group","status":"publish","type":"page","link":"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/","title":{"rendered":"Tumor Immunology – Geisberger Group"},"content":{"rendered":"\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
\n
\n
\n \n
\n
\n

Geisberger Group <\/h3>\n

Oncogenomics and tumor-immune interactions<\/p>\n\n <\/div>\n<\/div>\n <\/div>\n

\n
\n \n \n \n \n \"Roland\"\n <\/picture>\n \n <\/figure>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n
\n
\n
\n
\n
\n
\n

Research overview <\/h2>\n

The DNA of our cells is constantly damaged, e.g. by radiation, reactive metabolic products or errors during DNA duplication. Inaccurate repair of this DNA damage can lead to mutations, chromosomal changes and loss of genetic information, which can result in diseases, including cancer. In addition, defective DNA repair promotes the genetic heterogeneity of cancer cells, which can lead to the growth of therapy-resistant cancer cells, which represents a major clinical problem.<\/p>\n

In our research group, we investigate how DNA repair pathways are altered in cancer cells and we are looking for ways to harness these changes for better treatment approaches, especially with regard to efficient cancer defense by the body’s own immune system. Our aim is to understand all molecular, cellular and immunological aspects of our research topic in as broad a context as possible. We use a wide variety of molecular and biochemical methods and model systems, including cell lines, mouse models and primary human cancer samples with a particular focus on chronic lymphocytic leukemia.<\/p>\n\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n\n \n \n \n

\n
\n
\n \n
\n \n \n\n \n \n \n \n \n \n \n \"\"\n <\/picture>\n \n
Research concept: The sensitivity of cancer cells to certain therapeutic agents is characterized not only by cancer-intrinsic factors, but also by the interaction with cells of the microenvironment, i.e. immune cells. <\/figcaption>\n <\/figure>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
\n
\n
\n \n
\n
\n

Repair of DNA damage in cancer cells <\/h3>\n

Any change in the genetic information of a cell can lead to abnormal gene expression or gene activity and thus to diseases, including cancer. Almost every cancer cell exhibits genetic changes acquired through imprecise DNA repair. Cancer cells often use inaccurate or misdirected repair pathways to promote genetic variability from which “fitter” or (immune)therapy-resistant cancer cells can prevail, a process known as clonal evolution. In this research focus, we want to investigate mechanisms that are responsible for the diversification of genetic information during clonal cancer evolution. The aim is to find ways of preventing cancer cells from adapting to drugs and how cancer-specific repair pathways can be used as a starting point for targeted cancer therapies.<\/p>\n\n <\/div>\n<\/div>\n <\/div>\n

\n
\n \n \n \n \n \"\"\n <\/picture>\n \n
Image from: Ekaterina Akimova, Franz Josef Gassner, Richard Greil, Nadja Zaborsky, Roland Geisberger, Detecting Bacterial-Human Lateral Gene Transfer in Chronic Lymphocytic Leukemia <\/figcaption>\n <\/figure>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
\n
\n
\n \n
\n
\n

Tumor-immune interactions <\/h3>\n

During cancer growth, the cancer cells must constantly withstand an attack by the immune system. This constant interaction between cancer and the immune system alters both the cancer cells and the immune cells in a way that leads to immune system dysfunction and immunologically “invisible” tumor cells. In our research, we want to investigate tumor-immune interactions and the associated changes on the part of the immune system and the tumor from early to late stages of cancer in order to understand how the immune system is shut down by the cancer cells. In particular, we want to understand how attacks by the immune system affect genetic changes in cancer cells and how these in turn affect immune cells. The ultimate aim of these studies is to find ways of activating the body’s own immune cells, especially T lymphocytes, to enable a lasting and efficient fight against cancer cells.<\/p>\n\n <\/div>\n<\/div>\n <\/div>\n

\n
\n \n \n \n \n \"\"\n <\/picture>\n \n
Image credit: Ekaterina Akimova (Imaging Mass Cytometry on Leukemia infiltrated tissue) <\/figcaption>\n <\/figure>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
\n
\n
\n \n
\n
\n

Team <\/h3>\n

Roland Geisberger
\nGroup leader
\norcid ID: 0000-0002-0131-2191<\/p>\n

Ekaterina Akimova
\nPostDoc<\/p>\n

Philine Hoven
\nPhD student<\/p>\n

Dominik Baumgartner
\nPhD student<\/p>\n

Julia Moser
\nMaster Student<\/p>\n

Fiona Liebig
\nMaster Student<\/p>\n\n <\/div>\n<\/div>\n <\/div>\n

\n
\n \n \n \n \n \"\"\n <\/picture>\n \n <\/figure>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n\n
\n
\n
\n
\n
\n

Publications <\/ h3 >\n <\/div>\n <\/div>\n <\/div>\n<\/header>\n
\n
\n
\n
\n
\n
\n 2021\n <\/header>\n \n <\/a>\n <\/span>\n <\/div>\n <\/div>\n\n\n
\n
\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n \n \n
\n
\n
\n
\n
\n

Akimova E, Gassner FJ, Schubert M, Rebhandl S, Arzt C, Rauscher S, Tober V, Zaborsky N, Greil R, Geisberger R. SAMHD1 restrains aberrant nucleotide insertions at repair junctions generated by DNA end joining. Nucleic Acids Res. 2021 Mar 18;49(5):2598-2608. doi: 10.1093\/nar\/gkab051.<\/p>\n

Gassner FJ, Zaborsky N, Buchumenski I, Levanon EY, Gatterbauer M, Schubert M, Rauscher S, Hebenstreit D, Nadeu F, Campo E, Egle A, Greil R, Geisberger R. RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. Leukemia. 2021 Apr;35(4):1053-1063. doi: 10.1038\/s41375-020-0995-6. Epub 2020 Jul 30.<\/p>\n\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n
\n 2017\n <\/header>\n \n <\/a>\n <\/span>\n <\/div>\n <\/div>\n\n\n
\n
\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n \n \n
\n
\n
\n
\n
\n

Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC, Pleyer L, Egle A, Hartmann TN, Greil R, Geisberger R. TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology. 2017 Sep 21;7(1):e1371399. doi: 10.1080\/2162402X.2017.1371399.<\/p>\n

Gassner FJ, Schubert M, Rebhandl S, Spandl K, Zaborsky N, Catakovic K, Blaimer S, Hebenstreit D, Greil R, Geisberger R. Imprecision and DNA Break Repair Biased towards Incompatible End Joining in Leukemia. Mol Cancer Res. 2018 Mar;16(3):428-438. doi: 10.1158\/1541-7786.MCR-17-0373. Epub 2017 Dec 8.<\/p>\n\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n
\n 2014\n <\/header>\n \n <\/a>\n <\/span>\n <\/div>\n <\/div>\n\n\n
\n
\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n\n \n \n \n
\n
\n
\n
\n
\n

Rebhandl S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, Gr\u00f6ssinger EM, Greil R, Geisberger R. APOBEC3 signature mutations in chronic lymphocytic leukemia. Leukemia. 2014 Sep;28(9):1929-32. doi: 10.1038\/leu.2014.160. Epub 2014 May 20.<\/p>\n\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n

\n
\n
\n
\n
\n
\n

Do you have a request or questions? <\/h3>\n

Get in touch with us – we will get back to you as soon as possible.<\/p>\n

to the inquiry<\/a><\/p>\n\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n ","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"acf":[],"yoast_head":"\nTumor Immunology - Geisberger Group - LIMCR<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tumor Immunology - Geisberger Group - LIMCR\" \/>\n<meta property=\"og:url\" content=\"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/\" \/>\n<meta property=\"og:site_name\" content=\"LIMCR\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-14T07:54:40+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/\",\"url\":\"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/\",\"name\":\"Tumor Immunology - Geisberger Group - LIMCR\",\"isPartOf\":{\"@id\":\"https:\/\/limcr.rup-dev.net\/en\/#website\"},\"datePublished\":\"2023-08-09T07:45:10+00:00\",\"dateModified\":\"2024-02-14T07:54:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/limcr.rup-dev.net\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tumor Immunology – Geisberger Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/limcr.rup-dev.net\/en\/#website\",\"url\":\"https:\/\/limcr.rup-dev.net\/en\/\",\"name\":\"LIMCR\",\"description\":\"Just another scri-2022 site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/limcr.rup-dev.net\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tumor Immunology - Geisberger Group - LIMCR","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Tumor Immunology - Geisberger Group - LIMCR","og_url":"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/","og_site_name":"LIMCR","article_modified_time":"2024-02-14T07:54:40+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/","url":"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/","name":"Tumor Immunology - Geisberger Group - LIMCR","isPartOf":{"@id":"https:\/\/limcr.rup-dev.net\/en\/#website"},"datePublished":"2023-08-09T07:45:10+00:00","dateModified":"2024-02-14T07:54:40+00:00","breadcrumb":{"@id":"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/limcr.rup-dev.net\/en\/tumor-immunology-geisberger-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/limcr.rup-dev.net\/en\/"},{"@type":"ListItem","position":2,"name":"Tumor Immunology – Geisberger Group"}]},{"@type":"WebSite","@id":"https:\/\/limcr.rup-dev.net\/en\/#website","url":"https:\/\/limcr.rup-dev.net\/en\/","name":"LIMCR","description":"Just another scri-2022 site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/limcr.rup-dev.net\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/limcr.rup-dev.net\/en\/wp-json\/wp\/v2\/pages\/3094"}],"collection":[{"href":"https:\/\/limcr.rup-dev.net\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/limcr.rup-dev.net\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/limcr.rup-dev.net\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/limcr.rup-dev.net\/en\/wp-json\/wp\/v2\/comments?post=3094"}],"version-history":[{"count":7,"href":"https:\/\/limcr.rup-dev.net\/en\/wp-json\/wp\/v2\/pages\/3094\/revisions"}],"predecessor-version":[{"id":3118,"href":"https:\/\/limcr.rup-dev.net\/en\/wp-json\/wp\/v2\/pages\/3094\/revisions\/3118"}],"wp:attachment":[{"href":"https:\/\/limcr.rup-dev.net\/en\/wp-json\/wp\/v2\/media?parent=3094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}